nodes	percent_of_prediction	percent_of_DWPC	metapath
Fosaprepitant—TACR1—Peptide GPCRs—SSTR3—pancreatic cancer	0.0118	0.0335	CbGpPWpGaD
Fosaprepitant—TACR1—Peptide GPCRs—SSTR1—pancreatic cancer	0.0113	0.0322	CbGpPWpGaD
Fosaprepitant—TACR1—Peptide GPCRs—SSTR2—pancreatic cancer	0.0109	0.0309	CbGpPWpGaD
Fosaprepitant—TACR1—Peptide GPCRs—CCKBR—pancreatic cancer	0.0105	0.0299	CbGpPWpGaD
Fosaprepitant—TACR1—Peptide GPCRs—CCKAR—pancreatic cancer	0.00784	0.0223	CbGpPWpGaD
Fosaprepitant—TACR1—Peptide ligand-binding receptors—PRLHR—pancreatic cancer	0.00653	0.0185	CbGpPWpGaD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—SSTR1—pancreatic cancer	0.00623	0.0177	CbGpPWpGaD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—SSTR2—pancreatic cancer	0.006	0.017	CbGpPWpGaD
Fosaprepitant—TACR1—Peptide ligand-binding receptors—SSTR3—pancreatic cancer	0.00555	0.0158	CbGpPWpGaD
Fosaprepitant—TACR1—Peptide ligand-binding receptors—SSTR1—pancreatic cancer	0.00532	0.0151	CbGpPWpGaD
Fosaprepitant—TACR1—Peptide GPCRs—AGTR1—pancreatic cancer	0.00527	0.015	CbGpPWpGaD
Fosaprepitant—TACR1—Peptide ligand-binding receptors—PPY—pancreatic cancer	0.00522	0.0148	CbGpPWpGaD
Fosaprepitant—TACR1—Peptide ligand-binding receptors—SSTR2—pancreatic cancer	0.00512	0.0146	CbGpPWpGaD
Fosaprepitant—TACR1—G alpha (q) signalling events—CCKBR—pancreatic cancer	0.00501	0.0142	CbGpPWpGaD
Fosaprepitant—TACR1—Peptide ligand-binding receptors—CCKBR—pancreatic cancer	0.00495	0.0141	CbGpPWpGaD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—FOXM1—pancreatic cancer	0.00472	0.0134	CbGpPWpGaD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—CCKBR—pancreatic cancer	0.00448	0.0127	CbGpPWpGaD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—PRLHR—pancreatic cancer	0.00438	0.0124	CbGpPWpGaD
Fosaprepitant—TACR1—G alpha (q) signalling events—GAST—pancreatic cancer	0.00431	0.0122	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—GADD45A—pancreatic cancer	0.00418	0.0119	CbGpPWpGaD
Fosaprepitant—TACR1—G alpha (q) signalling events—CCK—pancreatic cancer	0.0039	0.0111	CbGpPWpGaD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—GAST—pancreatic cancer	0.00385	0.011	CbGpPWpGaD
Fosaprepitant—TACR1—Peptide ligand-binding receptors—CCK—pancreatic cancer	0.00385	0.0109	CbGpPWpGaD
Fosaprepitant—TACR1—G alpha (q) signalling events—CCKAR—pancreatic cancer	0.00373	0.0106	CbGpPWpGaD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—SSTR3—pancreatic cancer	0.00372	0.0106	CbGpPWpGaD
Fosaprepitant—TACR1—Peptide ligand-binding receptors—CCKAR—pancreatic cancer	0.00369	0.0105	CbGpPWpGaD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—SSTR1—pancreatic cancer	0.00357	0.0101	CbGpPWpGaD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—PPY—pancreatic cancer	0.0035	0.00995	CbGpPWpGaD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—CCK—pancreatic cancer	0.00348	0.0099	CbGpPWpGaD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—SSTR2—pancreatic cancer	0.00344	0.00976	CbGpPWpGaD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—SST—pancreatic cancer	0.00341	0.0097	CbGpPWpGaD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—CCKAR—pancreatic cancer	0.00334	0.00949	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—PRLHR—pancreatic cancer	0.00333	0.00947	CbGpPWpGaD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—CCKBR—pancreatic cancer	0.00332	0.00943	CbGpPWpGaD
Fosaprepitant—TACR1—Peptide ligand-binding receptors—SST—pancreatic cancer	0.00291	0.00829	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—SSTR3—pancreatic cancer	0.00283	0.00806	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—SSTR1—pancreatic cancer	0.00272	0.00772	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—PPY—pancreatic cancer	0.00266	0.00757	CbGpPWpGaD
Fosaprepitant—TACR1—G alpha (q) signalling events—GCG—pancreatic cancer	0.00263	0.00748	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—SSTR2—pancreatic cancer	0.00262	0.00743	CbGpPWpGaD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—CCK—pancreatic cancer	0.00258	0.00733	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—CCKBR—pancreatic cancer	0.00253	0.00718	CbGpPWpGaD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—CNR2—pancreatic cancer	0.00251	0.00715	CbGpPWpGaD
Fosaprepitant—TACR1—G alpha (q) signalling events—AGTR1—pancreatic cancer	0.00251	0.00713	CbGpPWpGaD
Fosaprepitant—TACR1—Peptide ligand-binding receptors—AGTR1—pancreatic cancer	0.00248	0.00704	CbGpPWpGaD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—CCKAR—pancreatic cancer	0.00247	0.00703	CbGpPWpGaD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—HES1—pancreatic cancer	0.00245	0.00695	CbGpPWpGaD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—GCG—pancreatic cancer	0.00235	0.00669	CbGpPWpGaD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—AGTR1—pancreatic cancer	0.00225	0.00638	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—RB1—pancreatic cancer	0.00209	0.00593	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—SCT—pancreatic cancer	0.00206	0.00585	CbGpPWpGaD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—HIF1A—pancreatic cancer	0.00205	0.00583	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—CCK—pancreatic cancer	0.00196	0.00558	CbGpPWpGaD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—SST—pancreatic cancer	0.00196	0.00556	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—CNR2—pancreatic cancer	0.00191	0.00544	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—GLP1R—pancreatic cancer	0.00191	0.00544	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—CCKAR—pancreatic cancer	0.00188	0.00535	CbGpPWpGaD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—CNR1—pancreatic cancer	0.0018	0.00513	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—SHH—pancreatic cancer	0.00172	0.00488	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—PTGS2—pancreatic cancer	0.00171	0.00487	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—PRLHR—pancreatic cancer	0.00171	0.00486	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—IAPP—pancreatic cancer	0.0017	0.00482	CbGpPWpGaD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—AGTR1—pancreatic cancer	0.00166	0.00473	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—CXCL8—pancreatic cancer	0.00166	0.00473	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—PTHLH—pancreatic cancer	0.00163	0.00463	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—PTCH1—pancreatic cancer	0.00163	0.00463	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—SSTR3—pancreatic cancer	0.0016	0.00455	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—CASP3—pancreatic cancer	0.00159	0.00452	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—GDI1—pancreatic cancer	0.00157	0.00446	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—GDI2—pancreatic cancer	0.00157	0.00446	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—CCND1—pancreatic cancer	0.00155	0.0044	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—SSTR1—pancreatic cancer	0.00154	0.00436	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—PPY—pancreatic cancer	0.00151	0.00428	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—MMP9—pancreatic cancer	0.0015	0.00427	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—SST—pancreatic cancer	0.00149	0.00423	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—SSTR2—pancreatic cancer	0.00148	0.0042	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—SSTR3—pancreatic cancer	0.00145	0.00413	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—CCKBR—pancreatic cancer	0.00143	0.00406	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—SSTR1—pancreatic cancer	0.00139	0.00396	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—CNR1—pancreatic cancer	0.00137	0.00391	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—PPY—pancreatic cancer	0.00137	0.00389	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—SSTR2—pancreatic cancer	0.00134	0.00382	CbGpPWpGaD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—CXCL8—pancreatic cancer	0.00133	0.00378	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—GCG—pancreatic cancer	0.00133	0.00377	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—CCKBR—pancreatic cancer	0.0013	0.00368	CbGpPWpGaD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—CASP3—pancreatic cancer	0.00127	0.00362	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—AGTR1—pancreatic cancer	0.00127	0.0036	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—MYC—pancreatic cancer	0.00124	0.00353	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—TGFB1—pancreatic cancer	0.00124	0.00352	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—GAST—pancreatic cancer	0.00123	0.00349	CbGpPWpGaD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—CTNNB1—pancreatic cancer	0.00123	0.00349	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—EGFR—pancreatic cancer	0.00122	0.00345	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—SCT—pancreatic cancer	0.00116	0.00331	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—TNF—pancreatic cancer	0.00116	0.00329	CbGpPWpGaD
Fosaprepitant—TACR1—Peptide ligand-binding receptors—CXCL8—pancreatic cancer	0.00114	0.00323	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—GAST—pancreatic cancer	0.00111	0.00317	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—CCK—pancreatic cancer	0.00111	0.00316	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—CNR2—pancreatic cancer	0.00108	0.00308	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—GLP1R—pancreatic cancer	0.00108	0.00308	CbGpPWpGaD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—VEGFA—pancreatic cancer	0.00108	0.00307	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—CCKAR—pancreatic cancer	0.00106	0.00303	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—SCT—pancreatic cancer	0.00106	0.003	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—TP53—pancreatic cancer	0.00102	0.0029	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—PRLHR—pancreatic cancer	0.00101	0.00287	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—CCK—pancreatic cancer	0.00101	0.00287	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—CNR2—pancreatic cancer	0.000983	0.00279	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—GLP1R—pancreatic cancer	0.000983	0.00279	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—CCKAR—pancreatic cancer	0.000967	0.00275	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—IAPP—pancreatic cancer	0.000958	0.00272	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—ZNRF3—pancreatic cancer	0.00095	0.0027	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—ACVR1B—pancreatic cancer	0.00095	0.0027	CbGpPWpGaD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—TNF—pancreatic cancer	0.000926	0.00263	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—PTHLH—pancreatic cancer	0.00092	0.00261	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—SHH—pancreatic cancer	0.000881	0.0025	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—IAPP—pancreatic cancer	0.00087	0.00247	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—SSTR3—pancreatic cancer	0.000859	0.00244	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—DTX1—pancreatic cancer	0.000859	0.00244	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—SST—pancreatic cancer	0.000841	0.00239	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—PTHLH—pancreatic cancer	0.000835	0.00237	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—PTCH1—pancreatic cancer	0.000835	0.00237	CbGpPWpGaD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—pancreatic cancer	0.000825	0.00235	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—SSTR1—pancreatic cancer	0.000824	0.00234	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—PPY—pancreatic cancer	0.000808	0.0023	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—SSTR2—pancreatic cancer	0.000793	0.00225	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—CNR1—pancreatic cancer	0.000777	0.00221	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—CCKBR—pancreatic cancer	0.000766	0.00218	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—SST—pancreatic cancer	0.000764	0.00217	CbGpPWpGaD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—CXCL8—pancreatic cancer	0.000762	0.00217	CbGpPWpGaD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—pancreatic cancer	0.000752	0.00214	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—GCG—pancreatic cancer	0.00075	0.00213	CbGpPWpGaD
Fosaprepitant—TACR1—G alpha (q) signalling events—PIK3CA—pancreatic cancer	0.00073	0.00207	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—DTX4—pancreatic cancer	0.00072	0.00205	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—GLI1—pancreatic cancer	0.00072	0.00205	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—AGTR1—pancreatic cancer	0.000715	0.00203	CbGpPWpGaD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—pancreatic cancer	0.00071	0.00202	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—CNR1—pancreatic cancer	0.000705	0.002	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—PPP2R5B—pancreatic cancer	0.0007	0.00199	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—NRP1—pancreatic cancer	0.0007	0.00199	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—GCG—pancreatic cancer	0.000681	0.00194	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—HEY2—pancreatic cancer	0.000674	0.00192	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—GAST—pancreatic cancer	0.000659	0.00187	CbGpPWpGaD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—pancreatic cancer	0.000653	0.00185	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—AGTR1—pancreatic cancer	0.00065	0.00185	CbGpPWpGaD
Fosaprepitant—Fatigue—Gemcitabine—pancreatic cancer	0.000628	0.000969	CcSEcCtD
Fosaprepitant—Muscular weakness—Epirubicin—pancreatic cancer	0.000626	0.000965	CcSEcCtD
Fosaprepitant—Alanine aminotransferase increased—Epirubicin—pancreatic cancer	0.000626	0.000965	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—HEY1—pancreatic cancer	0.000624	0.00177	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—SCT—pancreatic cancer	0.000624	0.00177	CbGpPWpGaD
Fosaprepitant—Pain—Gemcitabine—pancreatic cancer	0.000623	0.000961	CcSEcCtD
Fosaprepitant—Constipation—Gemcitabine—pancreatic cancer	0.000623	0.000961	CcSEcCtD
Fosaprepitant—Nausea—Erlotinib—pancreatic cancer	0.000623	0.000961	CcSEcCtD
Fosaprepitant—Decreased appetite—Fluorouracil—pancreatic cancer	0.000623	0.000961	CcSEcCtD
Fosaprepitant—Diarrhoea—Sunitinib—pancreatic cancer	0.000621	0.000958	CcSEcCtD
Fosaprepitant—Dysgeusia—Docetaxel—pancreatic cancer	0.00062	0.000957	CcSEcCtD
Fosaprepitant—Gastrointestinal disorder—Fluorouracil—pancreatic cancer	0.000618	0.000954	CcSEcCtD
Fosaprepitant—Abdominal distension—Epirubicin—pancreatic cancer	0.000617	0.000952	CcSEcCtD
Fosaprepitant—Feeling abnormal—Irinotecan—pancreatic cancer	0.000616	0.000951	CcSEcCtD
Fosaprepitant—Pain—Fluorouracil—pancreatic cancer	0.000613	0.000945	CcSEcCtD
Fosaprepitant—Gastrointestinal pain—Irinotecan—pancreatic cancer	0.000612	0.000944	CcSEcCtD
Fosaprepitant—Muscle spasms—Docetaxel—pancreatic cancer	0.000609	0.00094	CcSEcCtD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—pancreatic cancer	0.000604	0.00172	CbGpPWpGaD
Fosaprepitant—Dizziness—Sunitinib—pancreatic cancer	0.0006	0.000926	CcSEcCtD
Fosaprepitant—Feeling abnormal—Gemcitabine—pancreatic cancer	0.0006	0.000926	CcSEcCtD
Fosaprepitant—Abdominal pain upper—Doxorubicin—pancreatic cancer	0.0006	0.000925	CcSEcCtD
Fosaprepitant—Hypokalaemia—Doxorubicin—pancreatic cancer	0.000597	0.000922	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—CCK—pancreatic cancer	0.000596	0.00169	CbGpPWpGaD
Fosaprepitant—Body temperature increased—Irinotecan—pancreatic cancer	0.000591	0.000912	CcSEcCtD
Fosaprepitant—Abdominal pain—Irinotecan—pancreatic cancer	0.000591	0.000912	CcSEcCtD
Fosaprepitant—Aspartate aminotransferase increased—Doxorubicin—pancreatic cancer	0.000591	0.000912	CcSEcCtD
Fosaprepitant—Toxic epidermal necrolysis—Doxorubicin—pancreatic cancer	0.000591	0.000912	CcSEcCtD
Fosaprepitant—Feeling abnormal—Fluorouracil—pancreatic cancer	0.00059	0.000911	CcSEcCtD
Fosaprepitant—Anaemia—Docetaxel—pancreatic cancer	0.000586	0.000903	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—CNR2—pancreatic cancer	0.00058	0.00165	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—GLP1R—pancreatic cancer	0.00058	0.00165	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—CXCL8—pancreatic cancer	0.00058	0.00165	CbGpPWpGaD
Fosaprepitant—Alanine aminotransferase increased—Doxorubicin—pancreatic cancer	0.000579	0.000893	CcSEcCtD
Fosaprepitant—Muscular weakness—Doxorubicin—pancreatic cancer	0.000579	0.000893	CcSEcCtD
Fosaprepitant—Vomiting—Sunitinib—pancreatic cancer	0.000577	0.000891	CcSEcCtD
Fosaprepitant—Body temperature increased—Gemcitabine—pancreatic cancer	0.000576	0.000889	CcSEcCtD
Fosaprepitant—Dysuria—Epirubicin—pancreatic cancer	0.000573	0.000885	CcSEcCtD
Fosaprepitant—Rash—Sunitinib—pancreatic cancer	0.000572	0.000883	CcSEcCtD
Fosaprepitant—Dermatitis—Sunitinib—pancreatic cancer	0.000572	0.000882	CcSEcCtD
Fosaprepitant—Abdominal distension—Doxorubicin—pancreatic cancer	0.000571	0.000881	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—CCKAR—pancreatic cancer	0.000571	0.00162	CbGpPWpGaD
Fosaprepitant—Urticaria—Fluorouracil—pancreatic cancer	0.000569	0.000878	CcSEcCtD
Fosaprepitant—Headache—Sunitinib—pancreatic cancer	0.000569	0.000878	CcSEcCtD
Fosaprepitant—Syncope—Docetaxel—pancreatic cancer	0.000568	0.000876	CcSEcCtD
Fosaprepitant—Pollakiuria—Epirubicin—pancreatic cancer	0.000566	0.000874	CcSEcCtD
Fosaprepitant—Body temperature increased—Fluorouracil—pancreatic cancer	0.000566	0.000874	CcSEcCtD
Fosaprepitant—Palpitations—Docetaxel—pancreatic cancer	0.00056	0.000864	CcSEcCtD
Fosaprepitant—Photosensitivity reaction—Epirubicin—pancreatic cancer	0.00056	0.000864	CcSEcCtD
Fosaprepitant—Loss of consciousness—Docetaxel—pancreatic cancer	0.000557	0.000859	CcSEcCtD
Fosaprepitant—Weight decreased—Epirubicin—pancreatic cancer	0.000555	0.000856	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—JAG2—pancreatic cancer	0.000554	0.00157	CbGpPWpGaD
Fosaprepitant—Cough—Docetaxel—pancreatic cancer	0.000553	0.000853	CcSEcCtD
Fosaprepitant—Hypersensitivity—Irinotecan—pancreatic cancer	0.000551	0.00085	CcSEcCtD
Fosaprepitant—Hypertension—Docetaxel—pancreatic cancer	0.000547	0.000844	CcSEcCtD
Fosaprepitant—Infestation—Epirubicin—pancreatic cancer	0.000547	0.000844	CcSEcCtD
Fosaprepitant—Infestation NOS—Epirubicin—pancreatic cancer	0.000547	0.000844	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—MEN1—pancreatic cancer	0.000546	0.00155	CbGpPWpGaD
Fosaprepitant—Stevens-Johnson syndrome—Epirubicin—pancreatic cancer	0.000542	0.000836	CcSEcCtD
Fosaprepitant—Chest pain—Docetaxel—pancreatic cancer	0.000539	0.000832	CcSEcCtD
Fosaprepitant—Nausea—Sunitinib—pancreatic cancer	0.000539	0.000832	CcSEcCtD
Fosaprepitant—Asthenia—Irinotecan—pancreatic cancer	0.000537	0.000828	CcSEcCtD
Fosaprepitant—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—pancreatic cancer	0.000536	0.000826	CcSEcCtD
Fosaprepitant—Stomatitis—Epirubicin—pancreatic cancer	0.000533	0.000822	CcSEcCtD
Fosaprepitant—Conjunctivitis—Epirubicin—pancreatic cancer	0.000531	0.00082	CcSEcCtD
Fosaprepitant—Urinary tract infection—Epirubicin—pancreatic cancer	0.000531	0.00082	CcSEcCtD
Fosaprepitant—Dysuria—Doxorubicin—pancreatic cancer	0.000531	0.000819	CcSEcCtD
Fosaprepitant—Hypersensitivity—Fluorouracil—pancreatic cancer	0.000528	0.000814	CcSEcCtD
Fosaprepitant—Dry mouth—Docetaxel—pancreatic cancer	0.000527	0.000814	CcSEcCtD
Fosaprepitant—Pollakiuria—Doxorubicin—pancreatic cancer	0.000524	0.000809	CcSEcCtD
Fosaprepitant—Asthenia—Gemcitabine—pancreatic cancer	0.000523	0.000806	CcSEcCtD
Fosaprepitant—Haematuria—Epirubicin—pancreatic cancer	0.000521	0.000804	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—SHH—pancreatic cancer	0.000521	0.00148	CbGpPWpGaD
Fosaprepitant—Photosensitivity reaction—Doxorubicin—pancreatic cancer	0.000518	0.000799	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—NOTCH4—pancreatic cancer	0.000517	0.00147	CbGpPWpGaD
Fosaprepitant—Oedema—Docetaxel—pancreatic cancer	0.000517	0.000798	CcSEcCtD
Fosaprepitant—Anaphylactic shock—Docetaxel—pancreatic cancer	0.000517	0.000798	CcSEcCtD
Fosaprepitant—Pruritus—Gemcitabine—pancreatic cancer	0.000515	0.000795	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—IAPP—pancreatic cancer	0.000514	0.00146	CbGpPWpGaD
Fosaprepitant—Infection—Docetaxel—pancreatic cancer	0.000514	0.000792	CcSEcCtD
Fosaprepitant—Weight decreased—Doxorubicin—pancreatic cancer	0.000513	0.000792	CcSEcCtD
Fosaprepitant—Diarrhoea—Irinotecan—pancreatic cancer	0.000512	0.000789	CcSEcCtD
Fosaprepitant—Shock—Docetaxel—pancreatic cancer	0.000509	0.000785	CcSEcCtD
Fosaprepitant—Nervous system disorder—Docetaxel—pancreatic cancer	0.000507	0.000782	CcSEcCtD
Fosaprepitant—Pruritus—Fluorouracil—pancreatic cancer	0.000507	0.000782	CcSEcCtD
Fosaprepitant—Infestation—Doxorubicin—pancreatic cancer	0.000506	0.000781	CcSEcCtD
Fosaprepitant—Infestation NOS—Doxorubicin—pancreatic cancer	0.000506	0.000781	CcSEcCtD
Fosaprepitant—Skin disorder—Docetaxel—pancreatic cancer	0.000502	0.000775	CcSEcCtD
Fosaprepitant—Stevens-Johnson syndrome—Doxorubicin—pancreatic cancer	0.000502	0.000774	CcSEcCtD
Fosaprepitant—Bradycardia—Epirubicin—pancreatic cancer	0.0005	0.000771	CcSEcCtD
Fosaprepitant—Diarrhoea—Gemcitabine—pancreatic cancer	0.000498	0.000769	CcSEcCtD
Fosaprepitant—Dizziness—Irinotecan—pancreatic cancer	0.000495	0.000763	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—PTHLH—pancreatic cancer	0.000494	0.0014	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—PTCH1—pancreatic cancer	0.000494	0.0014	CbGpPWpGaD
Fosaprepitant—Stomatitis—Doxorubicin—pancreatic cancer	0.000493	0.000761	CcSEcCtD
Fosaprepitant—Urinary tract infection—Doxorubicin—pancreatic cancer	0.000492	0.000759	CcSEcCtD
Fosaprepitant—Conjunctivitis—Doxorubicin—pancreatic cancer	0.000492	0.000759	CcSEcCtD
Fosaprepitant—Diarrhoea—Fluorouracil—pancreatic cancer	0.00049	0.000756	CcSEcCtD
Fosaprepitant—Hypoaesthesia—Epirubicin—pancreatic cancer	0.000488	0.000753	CcSEcCtD
Fosaprepitant—Urinary tract disorder—Epirubicin—pancreatic cancer	0.000485	0.000748	CcSEcCtD
Fosaprepitant—Hypotension—Docetaxel—pancreatic cancer	0.000483	0.000745	CcSEcCtD
Fosaprepitant—Haematuria—Doxorubicin—pancreatic cancer	0.000482	0.000744	CcSEcCtD
Fosaprepitant—Connective tissue disorder—Epirubicin—pancreatic cancer	0.000482	0.000744	CcSEcCtD
Fosaprepitant—Urethral disorder—Epirubicin—pancreatic cancer	0.000481	0.000742	CcSEcCtD
Fosaprepitant—Vomiting—Irinotecan—pancreatic cancer	0.000476	0.000734	CcSEcCtD
Fosaprepitant—Dizziness—Fluorouracil—pancreatic cancer	0.000474	0.000731	CcSEcCtD
Fosaprepitant—Rash—Irinotecan—pancreatic cancer	0.000472	0.000728	CcSEcCtD
Fosaprepitant—Dermatitis—Irinotecan—pancreatic cancer	0.000471	0.000727	CcSEcCtD
Fosaprepitant—Headache—Irinotecan—pancreatic cancer	0.000469	0.000723	CcSEcCtD
Fosaprepitant—Insomnia—Docetaxel—pancreatic cancer	0.000468	0.000721	CcSEcCtD
Fosaprepitant—Erythema multiforme—Epirubicin—pancreatic cancer	0.000464	0.000716	CcSEcCtD
Fosaprepitant—Vomiting—Gemcitabine—pancreatic cancer	0.000463	0.000715	CcSEcCtD
Fosaprepitant—Bradycardia—Doxorubicin—pancreatic cancer	0.000462	0.000713	CcSEcCtD
Fosaprepitant—Dyspnoea—Docetaxel—pancreatic cancer	0.000461	0.000711	CcSEcCtD
Fosaprepitant—Somnolence—Docetaxel—pancreatic cancer	0.00046	0.000709	CcSEcCtD
Fosaprepitant—Rash—Gemcitabine—pancreatic cancer	0.000459	0.000709	CcSEcCtD
Fosaprepitant—Dermatitis—Gemcitabine—pancreatic cancer	0.000459	0.000708	CcSEcCtD
Fosaprepitant—Eye disorder—Epirubicin—pancreatic cancer	0.000459	0.000708	CcSEcCtD
Fosaprepitant—Tinnitus—Epirubicin—pancreatic cancer	0.000458	0.000706	CcSEcCtD
Fosaprepitant—Headache—Gemcitabine—pancreatic cancer	0.000456	0.000704	CcSEcCtD
Fosaprepitant—Flushing—Epirubicin—pancreatic cancer	0.000456	0.000703	CcSEcCtD
Fosaprepitant—Cardiac disorder—Epirubicin—pancreatic cancer	0.000456	0.000703	CcSEcCtD
Fosaprepitant—Vomiting—Fluorouracil—pancreatic cancer	0.000455	0.000703	CcSEcCtD
Fosaprepitant—Dyspepsia—Docetaxel—pancreatic cancer	0.000455	0.000702	CcSEcCtD
Fosaprepitant—Hypoaesthesia—Doxorubicin—pancreatic cancer	0.000452	0.000697	CcSEcCtD
Fosaprepitant—Rash—Fluorouracil—pancreatic cancer	0.000452	0.000697	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—SST—pancreatic cancer	0.000451	0.00128	CbGpPWpGaD
Fosaprepitant—Dermatitis—Fluorouracil—pancreatic cancer	0.000451	0.000696	CcSEcCtD
Fosaprepitant—Decreased appetite—Docetaxel—pancreatic cancer	0.000449	0.000693	CcSEcCtD
Fosaprepitant—Headache—Fluorouracil—pancreatic cancer	0.000449	0.000692	CcSEcCtD
Fosaprepitant—Urinary tract disorder—Doxorubicin—pancreatic cancer	0.000449	0.000692	CcSEcCtD
Fosaprepitant—Gastrointestinal disorder—Docetaxel—pancreatic cancer	0.000446	0.000689	CcSEcCtD
Fosaprepitant—Connective tissue disorder—Doxorubicin—pancreatic cancer	0.000446	0.000689	CcSEcCtD
Fosaprepitant—Fatigue—Docetaxel—pancreatic cancer	0.000446	0.000688	CcSEcCtD
Fosaprepitant—Angiopathy—Epirubicin—pancreatic cancer	0.000445	0.000687	CcSEcCtD
Fosaprepitant—Urethral disorder—Doxorubicin—pancreatic cancer	0.000445	0.000687	CcSEcCtD
Fosaprepitant—TACR1—GPCR downstream signaling—PIK3CG—pancreatic cancer	0.000445	0.00127	CbGpPWpGaD
Fosaprepitant—Nausea—Irinotecan—pancreatic cancer	0.000444	0.000685	CcSEcCtD
Fosaprepitant—Immune system disorder—Epirubicin—pancreatic cancer	0.000443	0.000684	CcSEcCtD
Fosaprepitant—Mediastinal disorder—Epirubicin—pancreatic cancer	0.000442	0.000682	CcSEcCtD
Fosaprepitant—Constipation—Docetaxel—pancreatic cancer	0.000442	0.000682	CcSEcCtD
Fosaprepitant—Pain—Docetaxel—pancreatic cancer	0.000442	0.000682	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—JAG1—pancreatic cancer	0.000442	0.00126	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—NOTCH3—pancreatic cancer	0.00044	0.00125	CbGpPWpGaD
Fosaprepitant—Nausea—Gemcitabine—pancreatic cancer	0.000433	0.000668	CcSEcCtD
Fosaprepitant—Mental disorder—Epirubicin—pancreatic cancer	0.00043	0.000663	CcSEcCtD
Fosaprepitant—Erythema multiforme—Doxorubicin—pancreatic cancer	0.000429	0.000662	CcSEcCtD
Fosaprepitant—Malnutrition—Epirubicin—pancreatic cancer	0.000427	0.000659	CcSEcCtD
Fosaprepitant—Erythema—Epirubicin—pancreatic cancer	0.000427	0.000659	CcSEcCtD
Fosaprepitant—Feeling abnormal—Docetaxel—pancreatic cancer	0.000426	0.000657	CcSEcCtD
Fosaprepitant—Nausea—Fluorouracil—pancreatic cancer	0.000425	0.000656	CcSEcCtD
Fosaprepitant—Eye disorder—Doxorubicin—pancreatic cancer	0.000424	0.000655	CcSEcCtD
Fosaprepitant—Tinnitus—Doxorubicin—pancreatic cancer	0.000423	0.000653	CcSEcCtD
Fosaprepitant—Gastrointestinal pain—Docetaxel—pancreatic cancer	0.000423	0.000652	CcSEcCtD
Fosaprepitant—Cardiac disorder—Doxorubicin—pancreatic cancer	0.000421	0.00065	CcSEcCtD
Fosaprepitant—Flushing—Doxorubicin—pancreatic cancer	0.000421	0.00065	CcSEcCtD
Fosaprepitant—Flatulence—Epirubicin—pancreatic cancer	0.000421	0.00065	CcSEcCtD
Fosaprepitant—Dysgeusia—Epirubicin—pancreatic cancer	0.000418	0.000646	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—CNR1—pancreatic cancer	0.000417	0.00118	CbGpPWpGaD
Fosaprepitant—Angiopathy—Doxorubicin—pancreatic cancer	0.000412	0.000636	CcSEcCtD
Fosaprepitant—Muscle spasms—Epirubicin—pancreatic cancer	0.000411	0.000634	CcSEcCtD
Fosaprepitant—Immune system disorder—Doxorubicin—pancreatic cancer	0.00041	0.000633	CcSEcCtD
Fosaprepitant—Mediastinal disorder—Doxorubicin—pancreatic cancer	0.000409	0.000631	CcSEcCtD
Fosaprepitant—Body temperature increased—Docetaxel—pancreatic cancer	0.000409	0.000631	CcSEcCtD
Fosaprepitant—Abdominal pain—Docetaxel—pancreatic cancer	0.000409	0.000631	CcSEcCtD
Fosaprepitant—TACR1—Signaling by GPCR—PIK3CG—pancreatic cancer	0.000404	0.00115	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—GCG—pancreatic cancer	0.000402	0.00114	CbGpPWpGaD
Fosaprepitant—Mental disorder—Doxorubicin—pancreatic cancer	0.000398	0.000614	CcSEcCtD
Fosaprepitant—Ill-defined disorder—Epirubicin—pancreatic cancer	0.000396	0.000612	CcSEcCtD
Fosaprepitant—Erythema—Doxorubicin—pancreatic cancer	0.000395	0.00061	CcSEcCtD
Fosaprepitant—Malnutrition—Doxorubicin—pancreatic cancer	0.000395	0.00061	CcSEcCtD
Fosaprepitant—Anaemia—Epirubicin—pancreatic cancer	0.000395	0.000609	CcSEcCtD
Fosaprepitant—TACR1—GPCR downstream signaling—PIK3CD—pancreatic cancer	0.000391	0.00111	CbGpPWpGaD
Fosaprepitant—Flatulence—Doxorubicin—pancreatic cancer	0.00039	0.000601	CcSEcCtD
Fosaprepitant—Dysgeusia—Doxorubicin—pancreatic cancer	0.000387	0.000597	CcSEcCtD
Fosaprepitant—Malaise—Epirubicin—pancreatic cancer	0.000385	0.000594	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—AGTR1—pancreatic cancer	0.000384	0.00109	CbGpPWpGaD
Fosaprepitant—Syncope—Epirubicin—pancreatic cancer	0.000383	0.000591	CcSEcCtD
Fosaprepitant—Hypersensitivity—Docetaxel—pancreatic cancer	0.000381	0.000588	CcSEcCtD
Fosaprepitant—Muscle spasms—Doxorubicin—pancreatic cancer	0.00038	0.000586	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—STK11—pancreatic cancer	0.000378	0.00108	CbGpPWpGaD
Fosaprepitant—Palpitations—Epirubicin—pancreatic cancer	0.000378	0.000583	CcSEcCtD
Fosaprepitant—Loss of consciousness—Epirubicin—pancreatic cancer	0.000376	0.000579	CcSEcCtD
Fosaprepitant—Cough—Epirubicin—pancreatic cancer	0.000373	0.000575	CcSEcCtD
Fosaprepitant—Asthenia—Docetaxel—pancreatic cancer	0.000371	0.000572	CcSEcCtD
Fosaprepitant—Hypertension—Epirubicin—pancreatic cancer	0.000369	0.000569	CcSEcCtD
Fosaprepitant—Ill-defined disorder—Doxorubicin—pancreatic cancer	0.000367	0.000566	CcSEcCtD
Fosaprepitant—Pruritus—Docetaxel—pancreatic cancer	0.000366	0.000564	CcSEcCtD
Fosaprepitant—Anaemia—Doxorubicin—pancreatic cancer	0.000365	0.000564	CcSEcCtD
Fosaprepitant—Chest pain—Epirubicin—pancreatic cancer	0.000364	0.000561	CcSEcCtD
Fosaprepitant—Anxiety—Epirubicin—pancreatic cancer	0.000363	0.000559	CcSEcCtD
Fosaprepitant—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	0.000361	0.000557	CcSEcCtD
Fosaprepitant—Discomfort—Epirubicin—pancreatic cancer	0.000359	0.000554	CcSEcCtD
Fosaprepitant—Malaise—Doxorubicin—pancreatic cancer	0.000357	0.00055	CcSEcCtD
Fosaprepitant—Dry mouth—Epirubicin—pancreatic cancer	0.000356	0.000549	CcSEcCtD
Fosaprepitant—TACR1—Signaling by GPCR—PIK3CD—pancreatic cancer	0.000355	0.00101	CbGpPWpGaD
Fosaprepitant—Syncope—Doxorubicin—pancreatic cancer	0.000355	0.000547	CcSEcCtD
Fosaprepitant—Diarrhoea—Docetaxel—pancreatic cancer	0.000354	0.000546	CcSEcCtD
Fosaprepitant—Palpitations—Doxorubicin—pancreatic cancer	0.000349	0.000539	CcSEcCtD
Fosaprepitant—Oedema—Epirubicin—pancreatic cancer	0.000349	0.000538	CcSEcCtD
Fosaprepitant—Anaphylactic shock—Epirubicin—pancreatic cancer	0.000349	0.000538	CcSEcCtD
Fosaprepitant—Loss of consciousness—Doxorubicin—pancreatic cancer	0.000347	0.000536	CcSEcCtD
Fosaprepitant—Infection—Epirubicin—pancreatic cancer	0.000346	0.000534	CcSEcCtD
Fosaprepitant—Cough—Doxorubicin—pancreatic cancer	0.000345	0.000532	CcSEcCtD
Fosaprepitant—Shock—Epirubicin—pancreatic cancer	0.000343	0.000529	CcSEcCtD
Fosaprepitant—Nervous system disorder—Epirubicin—pancreatic cancer	0.000342	0.000528	CcSEcCtD
Fosaprepitant—Dizziness—Docetaxel—pancreatic cancer	0.000342	0.000527	CcSEcCtD
Fosaprepitant—Hypertension—Doxorubicin—pancreatic cancer	0.000341	0.000527	CcSEcCtD
Fosaprepitant—TACR1—GPCR downstream signaling—PIK3CB—pancreatic cancer	0.000341	0.00097	CbGpPWpGaD
Fosaprepitant—Skin disorder—Epirubicin—pancreatic cancer	0.000339	0.000523	CcSEcCtD
Fosaprepitant—Hyperhidrosis—Epirubicin—pancreatic cancer	0.000337	0.00052	CcSEcCtD
Fosaprepitant—Chest pain—Doxorubicin—pancreatic cancer	0.000337	0.000519	CcSEcCtD
Fosaprepitant—Anxiety—Doxorubicin—pancreatic cancer	0.000335	0.000517	CcSEcCtD
Fosaprepitant—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	0.000334	0.000516	CcSEcCtD
Fosaprepitant—Discomfort—Doxorubicin—pancreatic cancer	0.000333	0.000513	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—SMAD4—pancreatic cancer	0.000331	0.000942	CbGpPWpGaD
Fosaprepitant—Dry mouth—Doxorubicin—pancreatic cancer	0.000329	0.000508	CcSEcCtD
Fosaprepitant—Vomiting—Docetaxel—pancreatic cancer	0.000329	0.000507	CcSEcCtD
Fosaprepitant—TACR1—GPCR downstream signaling—CXCL8—pancreatic cancer	0.000328	0.000932	CbGpPWpGaD
Fosaprepitant—Rash—Docetaxel—pancreatic cancer	0.000326	0.000503	CcSEcCtD
Fosaprepitant—Hypotension—Epirubicin—pancreatic cancer	0.000326	0.000503	CcSEcCtD
Fosaprepitant—Dermatitis—Docetaxel—pancreatic cancer	0.000326	0.000502	CcSEcCtD
Fosaprepitant—Headache—Docetaxel—pancreatic cancer	0.000324	0.0005	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—HES1—pancreatic cancer	0.000323	0.000919	CbGpPWpGaD
Fosaprepitant—Anaphylactic shock—Doxorubicin—pancreatic cancer	0.000323	0.000498	CcSEcCtD
Fosaprepitant—Oedema—Doxorubicin—pancreatic cancer	0.000323	0.000498	CcSEcCtD
Fosaprepitant—Infection—Doxorubicin—pancreatic cancer	0.000321	0.000495	CcSEcCtD
Fosaprepitant—Shock—Doxorubicin—pancreatic cancer	0.000317	0.00049	CcSEcCtD
Fosaprepitant—Nervous system disorder—Doxorubicin—pancreatic cancer	0.000316	0.000488	CcSEcCtD
Fosaprepitant—Insomnia—Epirubicin—pancreatic cancer	0.000315	0.000487	CcSEcCtD
Fosaprepitant—Skin disorder—Doxorubicin—pancreatic cancer	0.000313	0.000484	CcSEcCtD
Fosaprepitant—Hyperhidrosis—Doxorubicin—pancreatic cancer	0.000312	0.000481	CcSEcCtD
Fosaprepitant—Dyspnoea—Epirubicin—pancreatic cancer	0.000311	0.00048	CcSEcCtD
Fosaprepitant—Somnolence—Epirubicin—pancreatic cancer	0.00031	0.000478	CcSEcCtD
Fosaprepitant—TACR1—Signaling by GPCR—PIK3CB—pancreatic cancer	0.00031	0.00088	CbGpPWpGaD
Fosaprepitant—Nausea—Docetaxel—pancreatic cancer	0.000307	0.000474	CcSEcCtD
Fosaprepitant—Dyspepsia—Epirubicin—pancreatic cancer	0.000307	0.000474	CcSEcCtD
Fosaprepitant—Decreased appetite—Epirubicin—pancreatic cancer	0.000303	0.000468	CcSEcCtD
Fosaprepitant—Hypotension—Doxorubicin—pancreatic cancer	0.000302	0.000465	CcSEcCtD
Fosaprepitant—Gastrointestinal disorder—Epirubicin—pancreatic cancer	0.000301	0.000464	CcSEcCtD
Fosaprepitant—Fatigue—Epirubicin—pancreatic cancer	0.000301	0.000464	CcSEcCtD
Fosaprepitant—Pain—Epirubicin—pancreatic cancer	0.000298	0.00046	CcSEcCtD
Fosaprepitant—Constipation—Epirubicin—pancreatic cancer	0.000298	0.00046	CcSEcCtD
Fosaprepitant—TACR1—Signaling by GPCR—CXCL8—pancreatic cancer	0.000298	0.000846	CbGpPWpGaD
Fosaprepitant—Insomnia—Doxorubicin—pancreatic cancer	0.000292	0.00045	CcSEcCtD
Fosaprepitant—Dyspnoea—Doxorubicin—pancreatic cancer	0.000288	0.000444	CcSEcCtD
Fosaprepitant—Feeling abnormal—Epirubicin—pancreatic cancer	0.000287	0.000443	CcSEcCtD
Fosaprepitant—Somnolence—Doxorubicin—pancreatic cancer	0.000287	0.000443	CcSEcCtD
Fosaprepitant—Gastrointestinal pain—Epirubicin—pancreatic cancer	0.000285	0.00044	CcSEcCtD
Fosaprepitant—Dyspepsia—Doxorubicin—pancreatic cancer	0.000284	0.000438	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—TERT—pancreatic cancer	0.000283	0.000806	CbGpPWpGaD
Fosaprepitant—Decreased appetite—Doxorubicin—pancreatic cancer	0.00028	0.000433	CcSEcCtD
Fosaprepitant—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	0.000279	0.00043	CcSEcCtD
Fosaprepitant—Fatigue—Doxorubicin—pancreatic cancer	0.000278	0.000429	CcSEcCtD
Fosaprepitant—Urticaria—Epirubicin—pancreatic cancer	0.000277	0.000427	CcSEcCtD
Fosaprepitant—Pain—Doxorubicin—pancreatic cancer	0.000276	0.000426	CcSEcCtD
Fosaprepitant—Constipation—Doxorubicin—pancreatic cancer	0.000276	0.000426	CcSEcCtD
Fosaprepitant—Body temperature increased—Epirubicin—pancreatic cancer	0.000276	0.000425	CcSEcCtD
Fosaprepitant—Abdominal pain—Epirubicin—pancreatic cancer	0.000276	0.000425	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—HIF1A—pancreatic cancer	0.000271	0.00077	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—TSC2—pancreatic cancer	0.00027	0.000769	CbGpPWpGaD
Fosaprepitant—Feeling abnormal—Doxorubicin—pancreatic cancer	0.000266	0.00041	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—APOE—pancreatic cancer	0.000265	0.000752	CbGpPWpGaD
Fosaprepitant—Gastrointestinal pain—Doxorubicin—pancreatic cancer	0.000264	0.000407	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—KDR—pancreatic cancer	0.000259	0.000737	CbGpPWpGaD
Fosaprepitant—Hypersensitivity—Epirubicin—pancreatic cancer	0.000257	0.000396	CcSEcCtD
Fosaprepitant—Urticaria—Doxorubicin—pancreatic cancer	0.000256	0.000395	CcSEcCtD
Fosaprepitant—Body temperature increased—Doxorubicin—pancreatic cancer	0.000255	0.000394	CcSEcCtD
Fosaprepitant—Abdominal pain—Doxorubicin—pancreatic cancer	0.000255	0.000394	CcSEcCtD
Fosaprepitant—Asthenia—Epirubicin—pancreatic cancer	0.00025	0.000386	CcSEcCtD
Fosaprepitant—Pruritus—Epirubicin—pancreatic cancer	0.000247	0.000381	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—NFKBIA—pancreatic cancer	0.000247	0.000701	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—NOTCH1—pancreatic cancer	0.000244	0.000694	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—PIK3CG—pancreatic cancer	0.000239	0.000679	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—NRAS—pancreatic cancer	0.000239	0.000679	CbGpPWpGaD
Fosaprepitant—Diarrhoea—Epirubicin—pancreatic cancer	0.000239	0.000368	CcSEcCtD
Fosaprepitant—Hypersensitivity—Doxorubicin—pancreatic cancer	0.000238	0.000367	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—EGF—pancreatic cancer	0.000236	0.000671	CbGpPWpGaD
Fosaprepitant—Asthenia—Doxorubicin—pancreatic cancer	0.000232	0.000357	CcSEcCtD
Fosaprepitant—Dizziness—Epirubicin—pancreatic cancer	0.000231	0.000356	CcSEcCtD
Fosaprepitant—Pruritus—Doxorubicin—pancreatic cancer	0.000228	0.000352	CcSEcCtD
Fosaprepitant—Vomiting—Epirubicin—pancreatic cancer	0.000222	0.000342	CcSEcCtD
Fosaprepitant—Diarrhoea—Doxorubicin—pancreatic cancer	0.000221	0.000341	CcSEcCtD
Fosaprepitant—Rash—Epirubicin—pancreatic cancer	0.00022	0.000339	CcSEcCtD
Fosaprepitant—Dermatitis—Epirubicin—pancreatic cancer	0.00022	0.000339	CcSEcCtD
Fosaprepitant—Headache—Epirubicin—pancreatic cancer	0.000218	0.000337	CcSEcCtD
Fosaprepitant—TACR1—Signaling by GPCR—EGFR—pancreatic cancer	0.000218	0.000618	CbGpPWpGaD
Fosaprepitant—Dizziness—Doxorubicin—pancreatic cancer	0.000213	0.000329	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—PIK3CD—pancreatic cancer	0.00021	0.000597	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—PIK3CA—pancreatic cancer	0.000208	0.000591	CbGpPWpGaD
Fosaprepitant—Nausea—Epirubicin—pancreatic cancer	0.000207	0.00032	CcSEcCtD
Fosaprepitant—TACR1—Signaling by GPCR—KRAS—pancreatic cancer	0.000206	0.000584	CbGpPWpGaD
Fosaprepitant—Vomiting—Doxorubicin—pancreatic cancer	0.000205	0.000317	CcSEcCtD
Fosaprepitant—Rash—Doxorubicin—pancreatic cancer	0.000203	0.000314	CcSEcCtD
Fosaprepitant—Dermatitis—Doxorubicin—pancreatic cancer	0.000203	0.000314	CcSEcCtD
Fosaprepitant—Headache—Doxorubicin—pancreatic cancer	0.000202	0.000312	CcSEcCtD
Fosaprepitant—Nausea—Doxorubicin—pancreatic cancer	0.000192	0.000296	CcSEcCtD
Fosaprepitant—TACR1—Signaling by GPCR—PIK3CA—pancreatic cancer	0.000189	0.000537	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—PIK3CB—pancreatic cancer	0.000183	0.00052	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—CXCL8—pancreatic cancer	0.000176	0.0005	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—HRAS—pancreatic cancer	0.000175	0.000497	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—AKT1—pancreatic cancer	0.00017	0.000483	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—CASP3—pancreatic cancer	0.000168	0.000478	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—CCND1—pancreatic cancer	0.000164	0.000466	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—CTNNB1—pancreatic cancer	0.000162	0.000461	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—MMP9—pancreatic cancer	0.000159	0.000452	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—PTEN—pancreatic cancer	0.000158	0.000449	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—AKT1—pancreatic cancer	0.000154	0.000438	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—SRC—pancreatic cancer	0.000147	0.000417	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—VEGFA—pancreatic cancer	0.000143	0.000406	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—STAT3—pancreatic cancer	0.000141	0.000402	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—NRAS—pancreatic cancer	0.000141	0.000401	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—MYC—pancreatic cancer	0.000131	0.000374	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—TGFB1—pancreatic cancer	0.000131	0.000373	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—EGFR—pancreatic cancer	0.000129	0.000365	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—KRAS—pancreatic cancer	0.000121	0.000345	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—PIK3CA—pancreatic cancer	0.000112	0.000317	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—TP53—pancreatic cancer	0.000108	0.000307	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—HRAS—pancreatic cancer	0.000103	0.000293	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—AKT1—pancreatic cancer	9.11e-05	0.000259	CbGpPWpGaD
